With regard to the pathological significance and prognostic roles of HuR, several previous studies have reported that over-expression is associated with high-grade malignancy, advanced stage, and poor survival in patients with colon cancer [6], breast cancer [5], and renal cell carcinoma [7]. Here, ELAVL1 is linked to breast carcinoma.